DFTX
Definium Therapeutics Inc.

25,902
Mkt Cap
$1.67B
Volume
72.00
52W High
$18.70
52W Low
$4.70
PE Ratio
-8.59
DFTX Fundamentals
Price
$17.45
Prev Close
$16.95
Open
$17.05
50D MA
$15.19
Beta
1.82
Avg. Volume
2.28M
EPS (Annual)
-$1.54
P/B
9.96
Rev/Employee
$0.00
$238.52
Loading...
Loading...
News
all
press releases
Definium Therapeutics to Participate at Upcoming Investor Conferences
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address...
Business Wire·23h ago
News Placeholder
More News
News Placeholder
Definium Therapeutics (DFTX) to Release Quarterly Earnings on Thursday
Definium Therapeutics (NASDAQ:DFTX) will be releasing its Q4 2025 earnings after the market closes on Thursday, February 26. (View Earnings Report at...
MarketBeat·4d ago
News Placeholder
CenterBook Partners LP Takes Position in Definium Therapeutics, Inc. $DFTX
CenterBook Partners LP acquired a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·5d ago
News Placeholder
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address...
Business Wire·6d ago
News Placeholder
Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 8.3% - Still a Buy?
Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 8.3% - What's Next...
MarketBeat·7d ago
News Placeholder
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of "Buy" from Brokerages
Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have been assigned an average recommendation of "Buy" from the twelve research firms that are presently covering the stock...
MarketBeat·11d ago
News Placeholder
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Jefferies Financial Group
Jefferies Financial Group raised shares of Definium Therapeutics to a "strong-buy" rating in a research note on Thursday...
MarketBeat·25d ago
News Placeholder
Definium Therapeutics Appoints Roger Adsett to Board of Directors
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. We are thrilled to welcome Roger...
Business Wire·27d ago
News Placeholder
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to...
Business Wire·30d ago
News Placeholder
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
Royal Bank Of Canada lifted their target price on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an "outperform" rating in a report on Friday...
MarketBeat·1mo ago
<
1
2
...
>

Latest DFTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.